Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-10-07
1997-10-28
Furman, Keith C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
436 691, A61K 3817, A61K 3830, A61K 3818, C12N 1512
Patent
active
056818181
ABSTRACT:
This invention relates to polypeptides that are human somatomedin carrier protein subunits and to processes for producing them. The carrier protein subunits bind to human somatomedin-like polypeptides, also known as insulin-like growth factors. The process involves preparation from a human serum fraction, Cohn IV-1, by a molecule of various chromatographic steps.
This invention also relates to DNA molecules encoding human somatomedin carrier protein-like polypeptides, recombinant DNA molecules, hosts, processes for producing carrier protein-like polypeptides, human somatomedin carrier protein-like polypeptides produced using those molecules, hosts and processes. The invention relates to DNA molecules and their expression in appropriate hosts. The recombinant DNA molecules contain DNA molecules that code for polypeptides which have a biological activity of the human carrier protein or a human carrier protein subunit capable of binding somatomedins. The DNA molecules, recombinant DNA molecules, hosts, and processes of this invention may be used in the production of polypeptides useful in a variety of therapeutic, diagnostic, and other useful applications.
REFERENCES:
patent: 4394443 (1983-07-01), Weissman et al.
patent: 4642120 (1987-02-01), Nevo et al.
patent: 4703004 (1987-10-01), Hopp et al.
patent: 4727028 (1988-02-01), Santerre et al.
patent: 4738921 (1988-04-01), Belagaje et al.
patent: 4861757 (1989-08-01), Antaoniades et al.
patent: 4885163 (1989-12-01), Shaar et al.
patent: 5010100 (1991-04-01), Palva
patent: 5084384 (1992-01-01), Wong et al.
patent: 5104796 (1992-04-01), Keith et al.
patent: 5200509 (1993-04-01), Spencer et al.
patent: 5258287 (1993-11-01), Baxter et al.
patent: 5328891 (1994-07-01), Baxter et al.
Lyons et al. 1986, Molecular Cellular Endocrinology 45:263-270.
Gourmelen et al. (Abstract #85030792 of Dialog File 155), 1984. J. Clin. Endocrinol. Metab. 59:1197-1203.
Wood et al. 1988. Molecular Endocrinology.
Baxter et al. 1986. Biochem. Biophys Res. Comm. 139(3):1256-1261.
Baxter et al. 1986. J. Clin. Invest. 78:1504-1512.
Martin et al. 1986. J. Biol. Chem. 261(19):8754-8760.
Scheiweller et al. 1986. Nature 323:169-171.
Koirtinen et al. 1986. Endocrinology 118(4):1375-1378.
Povoa et al. 1985. Biochem Biophys. Res. Comm. 128(3):1071-1078.
Cohen et al., "The serum half-life of somatomedin activity: Evidence for growth hormone dependence" Acta Endocrinologica (1976) 83:243-258.
Zapf et al., "Inhibition of the action of nonsuppressible insulin-like activity on isolated rat fat cells by binding to its carrier protein" J. Clin. Invest. (1979) 63: 1077-1084.
Knauer et al., "Inhibition of biological activity of multiplication-stimulating activity by binding to its carrier protein" Proc. Natl. Acad. Sci. USA (1980) 77:7252-7256.
Drop et al., "Partial purification and characterization of a binding protein for insulin-like activity (ILAs) in human amniotic fluid: A possible inhibitor of insulin-like activity" Acta Endocrinologica (1979) 90:505-518.
Meuli et at., "NSILA-carrier protein abolishes the action of nonsuppressible insulin-like activity (NSILA-S) on perfused rat heart" Diabetologia (1978) 14:255-259.
Chochinov et al., "Characterization of a protein in mid-term human amniotic fluid which reacts in the somatomedin-C radioreceptor assay" J. Clin. Endocrinol. Metab. (1977) 44:902-908.
De Mellow et al., "Growth hormone-dependent insulin-like growth factor (IGF) binding protein both inhibits and potentiates IGF-I-stimulated DNA synthesis in human skin fibroblasts" Biochem. Biophys. Res. Commun. (1988) 156:199-204.
Blum et al., "Insulin-like growth factor I is a better mitogen if complexed with its binding protein" J. Endocrinol. Invest. (1987) 10(Suppl. 4):25.
Herington et al., "Identification of a specific inhibitor of nonsuppressible insulin-like activity in a partially purified human serum fraction" Endocrinology (1981) 109:1634-1640.
Ballard et al., "On the nomenclature of the IGF binding proteins" Acta Endocrinologica (1989) 121:751-752.
Abstract of Brewer et al., "Cloning, characterization, and expression of a human insulin-like growth factor binding protein" Biochem. Biophys. Res. Comm. (1988) 152:1289-1297.
Abstract of Brinkman et al., "Isolation and characterization of a complementary DNA encoding the low molecular weight insulin-like growth factor binding protein (IBP-1)" EMBO J. (1988) 7:2417-2424.
Abstract of International (PCT) Patent Publication No. WO 88/09818 (Dec. 15, 1988).
Morris et al., "Structure of somatomedin-binding protein: Alkaline pH-induced dissociation of an acid-stable, 60,000 molecular weight complex into smaller components" Endocrinol. (1982) 111:801-805.
Abstract of Furlanetto et al., "The somatomedin C binding protein: Evidence for a heterologous subunit structure" J. Clin. Endocrinol. Metab. (1980) 51:12-19.
Zapf et al., "Isolation and NH.sub.2 -terminal amino acid sequences of rat serum carrier proteins for insulin-like growth factors" Biochem. Biophys. Res. Comm. (1988) 156:1187-1194.
Abstract of International (PCT) Patent Publication No. WO 89/09792 (Oct. 19, 1989).
Abstract of International (PCT) Patent Publication No. WO 89/08666 (Sep. 21, 1989).
Smith, G.L., "Review-Somatomedin carrier proteins" Mol. Cell. Endocrinol. (1984) 34:83-89.
Drop et al., "Immunoassay of a somatomedin-binding protein from human amniotic fluid: Levels in fetal, neonatal, and adult sera" J. Clin. Endocrinol. Metab. (1984) 59:908-915.
Gourmelen et al., "Serum levels of insulin-like growth factor (IGF) and IGF binding protein in constitutionally tall children and adolescents" J. Clin. Endocrinol. Metab. (1984) 59:1197-1203.
Wood et al., "Cloning and expression of the growth hormone-dependent insulin-like growth factor-binding protein" Mol. Endocrinol. (1988) 2:1176-1185.
Baxter et al., "Growth hormone-dependent insulin-like growth factor (IGF) binding protein from human plasma differs from other human IGF binding proteins" Biochem. Biophys. Res. Comm. (1985) 139:1256-1261.
Baxter et al., "Radioimmunoassay of growth hormone-dependent insulinlike growth factor binding protein in human plasma" J. Clin. Invest. (1986) 78:1504-1512.
Martin et al., "Insulin-like growth factor-binding protein from human plasma purification and characterization" J. Biol. Chem. (1986) 261:8754-8760.
Schweiwiller et al., "Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I" Nature (1986) 323:169-171.
Koistinen et al., "Placental protein 12 is a decidual protein that binds somatomedin and has an identical N-terminal amino acid sequence with somatomedin-binding protein from human amniotic fluid" Endocrinol. (1986) 118:1375-1378.
Povoa et al., "The somatomedin-binding protein isolated from a human hepatoma cell line is identical to the human amniotic fluid somatomedin-binding protein" Biochem. Biophys. Res. Comm. (1985) 128:1071-1078.
Schmid et al., "Intact but not truncated insulin-like growth factor binding protein-3 (IGFBP-3) blocks IGF I-induced stimulation of osteoblasts: Control of IGF signalling to bone cells by IGFBP-3-specific proteolysis?" Biochem. Biophys. Res. Comm. (1991) 179:579-585.
Pratt et al., "Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation" Biochem. Biophys. Res. Comm. (1994) 198:292-297.
Cohen et al., "Transfection of the human insulin-like growth factor binding protein-3 gene into balb/c fibroblasts inhibits cellular growth" Mol. Endocrinol. (1993) 7:380-386.
Yee et al., "Insulin-like growth factor binding protein 1 expression inhibits insulin-like growth factor I action in MCF-7 breast cancer cells" Cell Growth & Differentiation (1994) 5:73-77.
Sommer et al., "Molecular genetics and actions of recombinant insulin-like growth factor binding protein-3" Modern Concepts of Insulin-Like Growth Factors (1991) Spencer, E.M., ed., Elsevier Science Publishing Co., Inc. New York, pp. 715-728.
Sommer et al., "Properties of glycosylated and non-glycosylated human recombinant IGF binding protein-3 (IGFBP-3)" Growth Regulation (1993) 3:46-49.
Kalu, "T
Spencer Emerald Martin
Talkington-Verser Carol
Celtrix Pharmaceuticals Inc.
Furman Keith C.
LandOfFree
Therapeutic uses of human somatomedin carrier proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic uses of human somatomedin carrier proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic uses of human somatomedin carrier proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1026153